Cronograma de promoção Geron Corporation
Parâmetros básicos
Nota
Subestimação
Nome | Significado | Nota |
P/S | 28.53 | 1 |
P/BV | 7.82 | 1 |
P/E | 0 | 0 |
Eficiência
Nome | Significado | Nota |
ROA | -35.32 | 0 |
ROE | -66.09 | 0 |
ROIC | -59.63 | 0 |
Dividendos
Nome | Significado | Nota |
Rendimento de dividendos | 0 | 0 |
DSI | 0 | 0 |
Crescimento médio dos dividendos | 0 | 0 |
Obrigação
Nome | Significado | Nota |
Debt/EBITDA | -0.786 | 10 |
Debt/Ratio | 0.2047 | 10 |
Debt/Equity | 1.12 | 8 |
Impulso de crescimento
Nome | Significado | Nota |
Receita, % | 30332.41 | 10 |
Ebitda, % | 106.74 | 10 |
EPS, % | -1.7 | 0 |
Dividendos
paper.price.prices
Preço | Common.min. | Common.max. | Mudar | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 1.56 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 1.6 $ | 0 $ | 0 $ | -2.5 % | 0 % | 0 % |
common.calendar.number_days.30d | 1.48 $ | 0 $ | 0 $ | +5.41 % | 0 % | 0 % |
common.calendar.number_days.90d | 1.39 $ | 1.18 $ | 1.62 $ | +12.23 % | 0 % | 0 % |
common.calendar.number_days.180d | 2.91 $ | 1.18 $ | 3.02 $ | -46.39 % | 0 % | 0 % |
common.calendar.number_days.1y | 4.66 $ | 1.18 $ | 4.78 $ | -66.52 % | 0 % | 0 % |
common.calendar.number_days.3y | 2.54 $ | 1.18 $ | 5.09 $ | -38.58 % | 0 % | 0 % |
common.calendar.number_days.5y | 1.82 $ | 0.99 $ | 5.09 $ | -14.29 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.8873 $ | 0.8873 $ | 6.38 $ | +175.81 % | 0 % | 0 % |
common.calendar.number_days.ytd | 2.94 $ | 1.18 $ | 3.6 $ | -46.94 % | 0 % | 0 % |
Principais proprietários
Contido em ETF
ETF | Compartilhar, % | Rentabilidade para o ano, % | Comissão, % |
Future Tech ETF | 0.27625 | 479.5 | 0.35 |
Principal Healthcare Innovators ETF | 0.27625 | -3.92 | 0.35 |
iShares Morningstar Small-Cap Growth ETF | 0.10126 | 570.49 | 0.06 |
iShares Morningstar Small-Cap ETF | 0.0513 | 301.34 | 0.25 |
0,18 | 336,85 | 0,25 |
---|
Empresas semelhantes
Gestão da empresa
Supervisor | Cargo | Pagamento | Ano de nascimento |
Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753.22k | 1964 (61 ano) |
Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | 1975 (50 anos) |
Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | 1962 (63 ano) |
Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1.53M | 1951 (74 ano) |
Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | |
Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | 1983 (42 ano) |
Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | N/A | 1967 (58 anos) |
Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 847.2k | 1964 (61 ano) |
Mr. Scott Samuels | Executive VP, Chief Legal Officer & Secretary | ||
Mr. James Ziegler M.B.A. | Executive VP & Chief Commercial Officer |
Informações da empresa
Site: http://www.geron.com
Sobre a empresa Geron Corporation
Корпорация "Герон", клиническая биофармацевтическая компания на поздней стадии, специализируется на разработке и коммерциализации методов лечения гематологических миелоидных злокачественных новообразований. Он обладает правами на иметелстат, ингибитор теломеразы в клинических испытаниях фазы 2F3, который ингибирует неконтролируемую пролиферацию злокачественных клеток-предшественников при гематологических миелоидных злокачественных опухолях, чтобы уменьшить дисфункциональную продукцию клеток крови и обеспечить восстановление нормальной продукции клеток крови. Компания была основана в 1990 году со штаб-квартирой в Менло-Парке, штат Калифорния.